The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Factors affecting serum levels of adipokines in Korean male patients withnonalcoholic fatty liver disease

한국 남성 비알코올성 지방간에서 혈청 adipokine 농도 변화에 영향을 미치는 요인

Oh, Se-Yong;Cho, Yong-Kyun;Yoo, Tae-Woo;Park, Jung-Ho;Kim, Hong-Joo;Park, Dong-Il;Sohn, Chong-Il;Jeon, Woo-Kyu;Kim, Byung-Ik;Jung, Chan-Hee;Rhee, Eun-Jung;Lee, Won-Young;Kim, Sun-Woo;Oh, Ki-Won;Yun, Eun-Joo;Oh, Eun-Sook
오세용;조용균;유태우;박정호;김홍주;박동일;손정일;전우규;김병익;정찬희;이은정;이원영;김선우;오기원;윤은주;오은숙

  • Published : 20060700
⟨ Previous Next ⟩

Abstract

Background : Adipokines are associated with various metabolic disorders including insulin resistance, obesity and dyslipidemia. Metabolic disorders have also been reported to be associated with nonalcoholic fatty liver disease (NAFLD). We aimed to estimate changes in serum adipokines levels according to the degrees of steatosis and to determine independent factors influencing serum adipokines levels in Korean male patients with NAFLD. Methods : 65 Korean male patients were subjected. The degrees of steatosis were stratified into the three groups, Group I: normal liver (27 subjects), Group II: mild fatty liver (24 subjects) and Group III: moderate to severe fatty liver (14 subjects), according to ultrasonographic liver findings. The anthropometric parameters, fasting serum adipokine levels including leptin, adiponectin and resistin were measured in all subjects. The level of insulin resistance was estimated using the HOMA-IR. Results : Serum leptin levels were significantly different among the three groups (mean\pmSD: Group I (2.052\pm1.071), Group II (2.879\pm1.016), Group III (4.457\pm1.965 ng/mL), p<0.001). Serum adiponectin and resistin levels were not significantly different among the three groups (p=0.184, p=0.649, respectively). BMI and HOMA-IR were independent factors of changes in serum leptin levels(p=0.026, p=0.001, respectively), but independent factors of changes in serum adiponectin and resistin levels were not observed. Conclusion : Our study support a indirect role to induce metabolic disorder for leptin in the pathogenesis of NAFLD, but do not support roles for adiponectin and resistin in the pathogenesis of NAFLD. BMI and HOMA-IR were only independent factors of changes in serum leptin levels.

목 적 : Adipokine은 인슐린 저항성, 비만 그리고 이상지질혈증 등의 다양한 대사질환과 관련이 있다. 또한 대사질환은 비알코올성 지방간질환과의 연관성이 알려져 있다. 저자들은 비알코올성 지방간질환에서 지방간 정도에 따른 혈청 adipokine 농도 변화와 혈청 adipokine 농도 변화에 영향을 미치는 독립적 위험인자를 알아보고 자 하였다. 방 법 : 한국 정상 성인 남자 65명을 대상으로 하였으며, 지방간 정도는 초음파에서 관찰되는 소견에 따라 Group I: 정상간(27명), Group II: 경도 지방간(24명), Group III: 중등도 이상의 지방간(14명) 세 군으로 분류하였다. 모든 대상자로부터 신체계측지표와 leptin, adiponectin 그리고 resistin의 공복 혈청 농도를 측정하였다. 인슐린 저항성은 HOMA-IR를 사용하여 평가하였다. 결 과 : 혈청 leptin 농도는 세 군 간에 유의한 차이가 있었다(평균\pm표준편차: Group I (2.052\pm1.071), Group II (2.879\pm1.016), Group III (4.457\pm1.965 ng/mL), p<0.001). 혈청 adiponectin과 resistin 농도는 세 군 간에 유의한 차이가 없었다(각각 p=0.184, p=0.649). 체질량지수와 HOMA-IR은 혈청 leptin 농도 변화에 대한 독립적 위험인자 이었으나(각각 p=0.026, p=0.001), 혈청 adiponectin과 resistin 농도 변화에 대한 독립적 위험인자는 관찰할 수 없었다. 결 론 : 본 연구에서 leptin은 비알코올성 지방간질환의 발생기전에 대사장애를 유도함으로써 간접적으로 관여함을 알 수 있었다. 그러나 adiponectin과 resistin은 비알코올성 지방간질환의 발생기전에 관련성이 있는지 알 수 없었다. 체질량지수와 HOMA-IR만이 혈청 leptin 농도 변화에 대한 독립적 위험인자 이었다.

Keywords

References

  1. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 41:943-949, 2004 https://doi.org/10.1016/j.jhep.2004.08.020
  2. Nakao K, Nakata K, Ohtsubo N, Maeda M, Moriuchi T, Ichikawa T, Hamasaki K, Kato Y, Eguchi K, Yukawa K, Ishii N. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol 97:1796-1801, 2002 https://doi.org/10.1111/j.1572-0241.2002.05846.x
  3. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: $TNF-\alpha$ or adiponectin? Hepatology 40:46-54, 2004 https://doi.org/10.1002/hep.20280
  4. Vuppalanchi R, Marri S, Kolwankar D, Considine RV, Chalasani N. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis?: a preliminary human study. J Clin Gastroenterol 39:237-242, 2005 https://doi.org/10.1097/01.mcg.0000152747.79773.2f
  5. Serin E, Ozer B, Gumurdulu Y, Kayaselcuk F, Kul K, Boyacioglu S. Serum leptin level can be a negative marker of hepatocyte damage in nonalcoholic fatty liver. J Gastroenterol 38:471-476, 2003 https://doi.org/10.1007/s00535-002-1084-5
  6. Kowdley KV, Pratt DS. Adiponectin: tipping the scales from NAFLD to NASH? Gastroenterology 128:511-513, 2005 https://doi.org/10.1053/j.gastro.2004.10.047
  7. Day CP, James OF. Steatohepatitis: a tale of two hits? Gastroenterology 114:842-845, 1998 https://doi.org/10.1016/S0016-5085(98)70599-2
  8. Kim SG, Kim HY, Seo JA, Lee KW, Oh JH, Kim NH, Choi KM, Baik SH, Choi DS. Relationship between serum adiponectin concentration, pulse wave velocity and nonalcoholic fatty liver disease. Eur J Endocrinol 152:225-231, 2005 https://doi.org/10.1530/eje.1.01842
  9. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54:117-121, 2005 https://doi.org/10.1136/gut.2003.037010
  10. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 53(Suppl 1):S143-S151, 2004 https://doi.org/10.2337/diabetes.53.2007.S143
  11. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 50:1511-1525, 2004 https://doi.org/10.1373/clinchem.2004.032482
  12. Lyon CJ, Law RE, Hsueh WA. Minireview: adipocyte, inflammation, and atherogenesis. Endocrinology 144:2195-2200, 2003 https://doi.org/10.1210/en.2003-0285
  13. Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, Considine RV. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 98:2771-2776, 2003 https://doi.org/10.1111/j.1572-0241.2003.08767.x
  14. Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, Deveci MS, Bagci S, Gulsen M, Karaeren N, Dagalp K. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 95:3584-3589, 2000 https://doi.org/10.1111/j.1572-0241.2000.03297.x
  15. Monzillo LU, Hamdy O, Horton ES, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa A, Mantzoros CS. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res 11:1048-1054, 2003 https://doi.org/10.1038/oby.2003.144
  16. Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, Scherer P, Rossetti L, Barzilai N. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokinemediated process? Diabetes 51:2951-2958, 2002
  17. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 409:307-312, 2001 https://doi.org/10.1038/35053000
  18. Muse ED, Obici S, Bhanot S, Monia BP, McKay RA, Rajala MW, Scherer PE, Rossetti L. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 114:232-239, 2004 https://doi.org/10.1172/JCI200421270
  19. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA. Resistin promotes endothelial cell activation: further evidence of adipokineendothelial interaction. Circulation 108:736-740, 2003 https://doi.org/10.1161/01.CIR.0000084503.91330.49
  20. Cohen P, Friedman JM. Leptin and the control of metabolism: role for stearoyl-CoA desaturase-1 (SCD-1). J Nutr 134:2455S-2463S, 2004
  21. Matthews DR, Hosker JP, Rudenski AS, Nayler BA, Treacher DF, Turner RL. Homeostatic model assessment: insulin resistance and $\beta-cell$ function from fasting plasma glucose and insulin concentration in man. Diabetologia 28:412-419, 1985 https://doi.org/10.1007/BF00280883
  22. Kurtz AB, Dubbins PA, Rubin CS, Kurtz RJ, Cooper HS, Cole-Beuglet C, Goldberg BB. Echogenicity: analysis, significance, and masking. AJR Am J Roentgenol 137:471-476, 1981 https://doi.org/10.2214/ajr.137.3.471
  23. Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, Sato N. Leptin augments inflammatory and profibrogenic response in the murine liver induced by hepatotoxic chemicals. Hepatology 34:288-297, 2001 https://doi.org/10.1053/jhep.2001.26518
  24. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Liddle C, Samarasinghe D, George J. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 36:403-409, 2002 https://doi.org/10.1053/jhep.2002.34738
  25. Liangpunsakul S, Chalasani N. Relationship between unexplained elevations in alanine aminotransferase and serum leptin in U.S. adults. J Clin Gastroenterol 38:891-897, 2004 https://doi.org/10.1097/00004836-200411000-00012
  26. Czaja MJ. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology 40:19-22, 2004 https://doi.org/10.1002/hep.20328
  27. Yokoyama H, Hirose H, Ohgo H, Saito I. Inverse association between serum adiponectin level and transaminase activities in Japanese male workers. J Hepatol 41:19-24, 2004 https://doi.org/10.1016/j.jhep.2004.03.003
  28. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Med 8:1288-1295, 2002 https://doi.org/10.1038/nm788
  29. Mendez-Sanchez N, Chavez-Tapia NC, Villa AR, Sanchez-Lara K, Zamora-Valdes D, Ramos MH, Uribe M. Adiponectin as a protective factor in hepatic steatosis. World J Gastroenterol 11:1737- 1741, 2005 https://doi.org/10.3748/wjg.v11.i12.1737
  30. Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, Yoshimatsu H. Adiponectin protects LPS-induced liver injury through modulation of $TNF-\alpha$ in KK-Ay obese mice. Hepatology 40:177-184, 2004 https://doi.org/10.1002/hep.20282
  31. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28:783-789, 2004 https://doi.org/10.1038/sj.ijo.0802625
  32. Vozarova de Courten B, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 53:1279-1284, 2004 https://doi.org/10.2337/diabetes.53.5.1279